Mr. Caitlin Lowie reports

SATELLOS ANNOUNCES FORAZAPADIN AS ASSIGNED INTERNATIONAL NONPROPRIETARY NAME FOR LEAD DRUG CANDIDATE, SAT-3247

Satellos Bioscience Inc. has assigned the international non-proprietary name (INN) "forazapadin" for the company's orally administered, small molecule drug candidate designed to restore muscle regeneration that was previously known as SAT-3247.

"As we continue to execute our clinical development strategies, this naming designation reflects the maturity of the program and supports its future development as we plan for regulatory submission and commercialization in Duchenne muscular dystrophy," said Frank Gleeson, co-founder and chief executive officer of Satellos. "Importantly, it comes amid a period of significant momentum across our Duchenne clinical programs, notably the expected completion of enrollment this quarter in the Basecamp study and the release of clinical data from the Basecamp study, which is expected in the fourth quarter."

The INN, assigned through the World Health Organization naming process, establishes a globally recognized, non-proprietary name for the therapy as forazapadin advances through clinical development and toward potential commercialization. Forazapadin is currently being evaluated in two phase 2 studies in patients with Duchenne muscular dystrophy (DMD) and the company intends to begin a phase 2 clinical trial in facioscapulohumeral muscular dystrophy (FSHD) by the end of 2026.

About forazapadin

Forazapadin is a proprietary, oral, small molecule drug candidate being developed by Satellos as a novel approach to regenerating skeletal muscle lost in DMD and other degenerative muscle diseases or injury conditions. Forazapadin targets AAK1, a key protein identified by Satellos as capable of helping restore the body's natural muscle repair and regeneration biology, a fundamental process that is disrupted in DMD and other degenerative conditions. By inhibiting AAK1, forazapadin treatment aims to re-establish a biochemical signal needed to support muscle regeneration. Satellos is advancing forazapadin as a potential treatment for DMD that is independent of dystrophin and applicable regardless of exon mutation status as either a stand-alone or adjunctive therapy, with continuing phase 2 clinical studies including Basecamp, a global, randomized, placebo-controlled study in pediatric participants, and Trailhead, an open-label study in adult participants.

The company previously referred to the program as SAT-3247 and expects to transition to broader use of the INN in future scientific, regulatory and corporate communications.

About Satellos Bioscience Inc.

Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed forazapadin, an orally administered small molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration. Forazapadin is being evaluated as a potential disease-modifying treatment, for DMD in two phase 2 clinical trials, Basecamp in pediatric participants with DMD and Trailhead in adults living with DMD, as well as for FSHD. The company has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development.

We seek Safe Harbor.